Cello Health PLC (LON:CLL)

Cello Health PLC (LON:CLL)

Share Price
126.00 p
7 (5.88 %)
Market Cap
£132.44 m
Proactive Investors - Run By Investors For Investors

Cello Health PLC

We are a global healthcare-focused advisory group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities.

We currently service 24 of the top 25 pharmaceutical clients globally as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.

We enable clients to differentiate their propositions and drive brand...

Market: AIM:CLL
52-week High/Low: 140.065p / 95.000p
Sector: Media & Publishing
Market Cap: £132.44 m
Website: cellohealth.com
col 3
col 4
col 5
col 6

Mark Scott, chief executive of Cello Health PLC (LON:CLL), pitches the company to investors. For more information visit www.cellohealthplc.com

Big Picture – A Deep Dive Examination of Cello Health PLC

Cello Health PLC Snapshot

Our mission is to be a truly global company of destination and distinction:

  • For our clients, as their preferred partner of choice, working with them to achieve commercial success.
  • For our people, to provide a rewarding environment that enables them to achieve their full potential.
  • For our shareholders, to help them benefit from the results of a prosperous and successful Group.

We will fulfil our mission by focusing on the following key strategic priorities:

  • Growth - to continue to drive organic growth across all of our key capabilities, expanding our global footprint, and specifically our presence within the US market.
  • Innovation - to continue to drive cutting edge innovation both in our thinking, our service offering and products, capitalising wherever possible on the latest technical and digital advances available.
  • Leveraging our key assets - through alignment of business development and client engagement across the business, as well as harmonised recruitment, training and incentives.

The Work We Do

Evaluating where to play in the microbiome

The landscape of the Human Microbiome is complex, with many factors influencing its development. Our client required a rigorous evaluation of the future landscape and creation of detailed future scenarios to enable them to make strategic business decisions. . to read further click here.


Oncology asset revenue royalty investment decision

To understand perceptions of physicians globally at a time when ovarian cancer treatment was experiencing a significant change due to the launch of 3-5 commercially similar, yet medically ground-breaking products..to read further click here.


The life changing value of medicine

The debate around the price of medicines has become loud, one-sided, and framed through the lens of ‘price in isolation’. As long as the debate is framed in this way, the pharmaceutical industry will struggle to be anything other than the ‘bad guy’, putting price barriers in the way of access to life-changing medicines. To read further click here.


Mapping of online behaviour and influence in severe asthma

Our client was preparing for launch of a new treatment for severe asthma. As part of the launch strategy they wanted to develop a patient mobilisation program to engage with patients in the early stages of the treatment journey. To read further click here.


Early detection of HIV
The provision of HIV testing beyond Genito-Urinary Medicine, into settings where people are most likely to use them, has proved a complex issue.. to read further click here.

Please click here for information on the Board.

Cello Health Insight


11-13 Charterhouse Buildings

t: +44 (0)20 7608 9300
e: [email protected]

New York

264 West 40th Street
Floor 16
New York
NY 10018

t: +1 646 837 8151
e: [email protected]


5250 Old Orchard Road
Suite 300
IL 60077

t: +1 847 983 3686
e: [email protected]

San Francisco - ProMedica

577 Airport Boulevard
Suite 130
CA 94010

t: +1 650 344 6242
e: [email protected]

Cello Health Consulting


Cello House
West St
Farnham, Surrey

t: +44 (0)1252 748 600
e: [email protected]

New York

264 West 40th Street
Floor 16
New York
NY 10018

t: +1 646 837 8151
e: [email protected]

New Jersey - Defined Health

25-B Hanover Road
Suite 320
Florham Park
NJ 07932

t: +1 973 292 5001
e: [email protected]

Cello Health Communications


Cello House
West St
Farnham, Surrey

t: +44 (0)1252 733 353
e: [email protected]


790 Township Line Road
Suite 200
PA 19067

See Google map

t: +1 215 504 5082
e: [email protected]


325 Chestnut Street, Suite 903
Philadelphia, PA 19106, USA

See Google map

t: +1 267 270 4840
e: [email protected]

Nominated Advisor and Broker

Cenkos Securities plc | 6.7.8 Tokenhouse Yard | London | EC2R 7AS


PricewaterhouseCoopers LLP | 1 Embankment Place | London | WC2N 6RH


Royal Bank of Scotland | 280 Bishopsgate | London | EC2M 4RB


Marriott Harrison | Staple Court | 11 Staple Inn Buildings | London | WC1V 7QH

Financial PR

Buchanan | 107 Cheapside | London | EC2V 6DN


Computershare | The Pavillions | Bridgwater Road | Bristol | BS13 8AE


Columns Including CLL


Market Reports Including CLL

Video RSS



© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use